Supplementary Figure S7 from Leveraging Longitudinal Patient-Reported Outcome Trajectories to Predict Survival in Non–Small Cell Lung Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Supplementary Figure S7. Impact of disease stage on PRO progression. The effect of disease stage on PRO progression was assessed using the SLP parameter. No statistically significant differences were observed across stages (ANOVA, p = 0.39) in the NSCLC Phase III clinical trial (NCT00532155). Subgroup sample sizes were as follows: Stage I, N = 24; Stage II, N = 10; Stage III, N = 111; and Stage IV or unknown stage, N = 223.